Connor D F, Rubin J
University of Connecticut School of Medicine, Farmington, Connecticut 06030-1410, USA.
Drugs Today (Barc). 2010 May;46(5):299-314. doi: 10.1358/dot.2010.46.5.1450095.
Extended-release guanfacine (Intuniv) is a novel long-acting, once-daily formulation of guanfacine indicated for attention deficit hyperactivity disorder (ADHD) in 6 to 17 year old children and adolescents. In doses 1 to 4 mg/day, guanfacine extended release (GXR) significantly improves the symptoms of inattention and hyperactivity-impulsivity in ADHD youngsters compared with placebo. Because of different pharmacokinetics, GXR is not substitutable on a mg-for-mg basis with immediate release guanfacine. Although extended release guanfacine does not demonstrate clinically significant ECG changes, mild slowing of the heart rate and some lowering of SBP and DBP does occur and requires vital sign monitoring during treatment. Children with a clinically significant cardiovascular history are not eligible for GXR therapy. Future research is exploring GXR effectiveness in ADHD complicated by oppositional defiant symptoms, ADHD complicated by tic disorders, posttraumatic stress disorders, and impulsive aggression in ADHD youngsters.
缓释胍法辛（Intuniv）是一种新型长效制剂，每日服用一次，用于治疗6至17岁儿童及青少年的注意力缺陷多动障碍（ADHD）。与安慰剂相比，剂量为1至4毫克/天的缓释胍法辛（GXR）能显著改善ADHD青少年的注意力不集中和多动冲动症状。由于药代动力学不同，GXR不能与速释胍法辛按毫克对毫克的比例相互替代。虽然缓释胍法辛未显示出具有临床意义的心电图变化，但确实会出现心率轻度减慢以及收缩压和舒张压有所降低的情况，因此治疗期间需要监测生命体征。有临床显著心血管病史的儿童不符合GXR治疗条件。未来的研究正在探索GXR在伴有对立违抗症状的ADHD、伴有抽动障碍的ADHD、创伤后应激障碍以及ADHD青少年的冲动攻击行为中的有效性。
